Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chemotherapy Induced Neutropenia Overview 10 Therapeutics Development 11 Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11 Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12 Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13 Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 15 Chemotherapy Induced Neutropenia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Chemotherapy Induced Neutropenia - Products under Development by Companies 20 Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 22 Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 23 Apotex Inc. 23 Biogenomics Limited 24 Bolder Biotechnology, Inc. 25 Cellerant Therapeutics, Inc. 26 Chong Kun Dang Pharmaceutical Corp. 27 Cinfa Biotech S.L. 28 Dr. Reddy's Laboratories Limited 29 Generon (Shanghai) Corporation Ltd. 30 Genexine, Inc. 31 Hanmi Pharmaceuticals, Co. Ltd. 32 Myelo Therapeutics GmbH 33 Octapharma AG 34 Pfenex Inc. 35 Pfizer Inc. 36 PharmaEssentia Corporation 37 Reliance Life Sciences Pvt. Ltd. 38 Richter Gedeon Nyrt. 39 Sandoz International GmbH 40 UAB Profarma 41 USV Limited 42 Chemotherapy Induced Neutropenia - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 BBT-007 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BBT-015 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BBT-018 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 EC-18 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 eflapegrastim - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 F-627 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 filgrastim - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 filgrastim - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 filgrastim - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 filgrastim - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 filgrastim - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 filgrastim - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GW-003 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 GXG-3 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 HSA-GCSF - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Myelo-001 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 pegfilgrastim - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pegfilgrastim - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 pegfilgrastim - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 pegfilgrastim - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 pegfilgrastim - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 pegfilgrastim - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 pegfilgrastim - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pegfilgrastim - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 pegfilgrastim - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pegfilgrastim - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pegfilgrastim - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 pegfilgrastim - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 pegfilgrastim - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 romyelocel-L - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TXA-302 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 WBI-2100 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Chemotherapy Induced Neutropenia - Recent Pipeline Updates 86 Chemotherapy Induced Neutropenia - Dormant Projects 93 Chemotherapy Induced Neutropenia - Discontinued Products 95 Chemotherapy Induced Neutropenia - Product Development Milestones 96 Featured News & Press Releases 96 Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 96 Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer 96 Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 97 Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 99 May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 99 Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 100 Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 100 May 10, 2011: Dr Reddy’s Launches Pegfilgrastim In India Under Brand Name Peg-grafeel 101 Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 101 Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology 102 Appendix 103 Methodology 103 Coverage 103 Secondary Research 103 Primary Research 103 Expert Panel Validation 103 Contact Us 103 Disclaimer 104

List of Tables Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2016 11 Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Comparative Analysis by Unknown Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc., H1 2016 23 Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H1 2016 24 Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H1 2016 25 Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016 26 Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 27 Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech S.L., H1 2016 28 Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 29 Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 30 Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H1 2016 31 Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 32 Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2016 33 Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2016 34 Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H1 2016 35 Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H1 2016 36 Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H1 2016 37 Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016 38 Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2016 39 Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2016 40 Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H1 2016 41 Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Number of Products by Stage and Target, H1 2016 45 Number of Products by Stage and Mechanism of Action, H1 2016 47 Number of Products by Stage and Route of Administration, H1 2016 49 Number of Products by Stage and Molecule Type, H1 2016 51 Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H1 2016 86 Chemotherapy Induced Neutropenia - Dormant Projects, H1 2016 93 Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H1 2016 94 Chemotherapy Induced Neutropenia - Discontinued Products, H1 2016 95 List of Figures Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2016 11 Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 43 Number of Products by Targets, H1 2016 44 Number of Products by Stage and Targets, H1 2016 44 Number of Products by Mechanism of Actions, H1 2016 46 Number of Products by Stage and Mechanism of Actions, H1 2016 46 Number of Products by Top 10 Routes of Administration, H1 2016 48 Number of Products by Stage and Routes of Administration, H1 2016 48 Number of Products by Molecule Types, H1 2016 50 Number of Products by Stage and Molecule Types, H1 2016 50

Apotex Inc. Biogenomics Limited Bolder Biotechnology, Inc. Cellerant Therapeutics, Inc. Chong Kun Dang Pharmaceutical Corp. Cinfa Biotech S.L. Dr. Reddy's Laboratories Limited Generon (Shanghai) Corporation Ltd. Genexine, Inc. Hanmi Pharmaceuticals, Co. Ltd. Myelo Therapeutics GmbH Octapharma AG Pfenex Inc. Pfizer Inc. PharmaEssentia Corporation Reliance Life Sciences Pvt. Ltd. Richter Gedeon Nyrt. Sandoz International GmbH UAB Profarma